View Older Stories View More Recent Stories

May 1, 2018 07:47AM AbbVie (ABBV) Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock
May 1, 2018 07:47AM AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock
Apr 30, 2018 11:35AM AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology
Apr 27, 2018 08:10AM AbbVie (ABBV) Highlights New Investigational Data for Elagolix at 2018 ACOG Meetings
Apr 27, 2018 08:00AM AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
Apr 26, 2018 07:47AM AbbVie Reports First-Quarter 2018 Financial Results
Apr 25, 2018 08:45AM AbbVie (ABBV) Submits BLA to FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
Apr 25, 2018 08:45AM AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
Apr 25, 2018 08:36AM AbbVie (ABBV) Says Upadacitinib Met Primary and Key Efficacy Endpoints in Phase 2b/3 RA Study in Japanese Patients
Apr 25, 2018 08:30AM AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
Apr 18, 2018 08:00AM AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference
Apr 10, 2018 08:15AM AbbVie (ABBV), Neurocrine Biosciences (NBIX) Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
Apr 10, 2018 08:15AM AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
Apr 9, 2018 08:47AM AbbVie (ABBV) Says Upadacitinib Met All Primary, Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in RA
Apr 9, 2018 08:45AM Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis
Apr 6, 2018 08:00AM AbbVie to Host First-Quarter 2018 Earnings Conference Call
Apr 5, 2018 08:11AM AbbVie (ABBV) Confirms Resolution of HUMIRA Patent Disputes with Samsung Bioepis
Apr 5, 2018 08:09AM Biogen (BIIB) & Samsung Bioepis Report Settlement with AbbVie (ABBV) for Commercialization of IMRALDI (Adalimumab Biosimilar) in Europe
Apr 5, 2018 08:05AM Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe
Apr 5, 2018 08:05AM AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis
Mar 22, 2018 08:46AM AbbVie (ABBV) Announces Results from Phase 2 Study Evaluating Rova-T for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory SCLC
Mar 22, 2018 08:45AM AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T) for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer
Mar 21, 2018 09:00AM AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma
Mar 13, 2018 08:01AM AbbVie (ABBV) Says Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids Met Primary Endpoint
Mar 13, 2018 08:00AM AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Mar 5, 2018 08:00AM Julianne Hough Encourages Women to "Speak Up for Endo" during Endometriosis Awareness Month
Mar 2, 2018 05:56AM AbbVie (ABBV) & Biogen (BIIB) Report Voluntary Global Withdrawal of Marketing Authorizations for ZINBRYTA (Daclizumab)
Mar 2, 2018 05:07AM Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis
Feb 26, 2018 08:00AM AbbVie to Present at the Barclays Global Healthcare Conference
Feb 22, 2018 08:00AM AbbVie to Present at the Cowen and Company 38th Annual Health Care Conference
Feb 21, 2018 08:01AM AbbVie (ABBV) Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids Met Its Primary Endpoint
Feb 21, 2018 08:00AM AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Feb 20, 2018 07:03AM Voyager Therapeutics (VYGR), AbbVie (ABBV) Enter Pact to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases
Feb 20, 2018 07:00AM AbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer's Disease and Other Tau-Related Neurodegenerative Diseases
Feb 20, 2018 07:00AM Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases
Feb 20, 2018 05:49AM AbbVie (ABBV) Announced New Positive Results from Phase 2b Data on Upadacitinib in Atopic Dermatitis
Feb 17, 2018 04:50PM AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting
Feb 17, 2018 04:00PM AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Feb 16, 2018 11:21AM AbbVie (ABBV) Reports New Phase 2 Data for Upadacitinib Showing Clinical & Endoscopic Outcomes in Crohn's Disease at 52 Weeks
Feb 16, 2018 11:20AM AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks
Feb 15, 2018 12:49PM AbbVie Increases Dividend and Announces New Stock Repurchase Program
Feb 14, 2018 05:45PM Glenview Capital 13F Shows New Stakes in Allergan (AGN), Newell (NWL), Charter (CHTR) Aramark (ARMK) (More...)
Feb 12, 2018 08:04AM AbbVie (ABBV) Showcases New, Late-Breaking Investigational Data at AAD Meeting
Feb 12, 2018 08:00AM AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting
Jan 26, 2018 07:51AM AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results
Jan 12, 2018 08:00AM AbbVie to Host Fourth-Quarter 2017 Earnings Conference Call
Jan 8, 2018 08:09AM AbbVie (ABBV) Says Upadacitinib Granted Breakthrough Therapy Designation FDA for Atopic Dermatitis
Jan 8, 2018 08:00AM AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis
Dec 20, 2017 08:02AM AbbVie's (ABBV) Upadacitinib Phase 3 Rheumatoid Arthritis Study Meets All Primary and Key Secondary Endpoints
Dec 20, 2017 08:00AM AbbVie to Present at the 36th Annual J.P. Morgan Healthcare Conference
View More Recent Stories View Older Stories